Mediwound Ltd
MDWD
View Detailed Chart
17.025USD
+0.315+1.89%
Market hours （ET）Quotes delayed by 15 min
185.16MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.89%
5 Days
-7.72%
1 Month
-5.94%
6 Months
-10.82%
Year to Date
-4.35%
1 Year
-8.12%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
30.667
Target Price
+79.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 20.22M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 54.21.
Fairly Valued
The company’s latest PE is -6.42, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.70M shares, decreasing 14.06% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 369.08K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Ticker SymbolMDWD
CompanyMediwound Ltd
CEOMr. Ofer Gonen
Websitehttps://www.mediwound.com/
Related Instruments
+0.75%
-0.93%
-0.32%
-1.45%
-0.18%
+6.22%
+0.17%
+0.10%
+0.89%
+0.37%
+0.64%
-0.02%
-0.69%
-0.05%
-0.36%
-1.38%
-0.00%
+0.37%
+0.87%
-0.61%
